


RSC Advances



This article can be cited before page numbers have been issued, to do this please use: F. Xu, J. Li, T. Zhu, S. Yu, C. Zuo, R. Yao and H. Qian, *RSC Adv.*, 2016, DOI: 10.1039/C6RA23440B.



This is an *Accepted Manuscript*, which has been through the Royal Society of Chemistry peer review process and has been accepted for publication.

Accepted Manuscripts are published online shortly after acceptance, before technical editing, formatting and proof reading. Using this free service, authors can make their results available to the community, in citable form, before we publish the edited article. This *Accepted Manuscript* will be replaced by the edited, formatted and paginated article as soon as this is available.

You can find more information about *Accepted Manuscripts* in the [Information for Authors](#).

Please note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal's standard [Terms & Conditions](#) and the [Ethical guidelines](#) still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this *Accepted Manuscript* or any consequences arising from the use of any information it contains.

**A New Trick (Hydroxyl radical generation) of an Old Vitamin (B₂)
for Near-infrared-triggered Photodynamic Therapy**

Fang Xu*,^a, Jin Li^a, Ting-ting Zhu^{a,b}, Sheng-Song Yu^b, Chong Zuo^a, Ri-sheng Yao^a
and Hai-sheng Qian^a

^aDepartment of Pharmaceutical Engineering, Hefei University of Technology, Hefei, 230009, China; ^bDepartment of Chemistry, University of Science & Technology of China, Hefei, 230026, China.

Corresponding author:

Fang Xu, E-mail: Fangxu@hfut.edu.cn; Fax: +86 551 62901771

ABSTRACT:

Photosensitizer has been supposed to the key component in photodynamic therapy (PDT). Natural products and their intricate molecular frameworks are often used as starting points for drug discovery. Riboflavin (RF), also known as vitamin B₂, bearing a unique conjugate structure of isoalloxazine ring, is a potential photosensitizer for use in the PDT of cancers. In this study, we present a novel near-infrared (NIR) mediated nanocomposite for PDT, using this old vitamin as a PDT photosensitizer, integrated with the upconversion nanotechnology. Mesoporous-silica-coated NaYF₄:Yb/Tm nanoparticles were fabricated and used as drug carriers and photo-transducers. Chemical modification of RF was performed to obtain a photostable photosensitizer (2',3',4',5'-tetraacetylriboflavin, RTA). There is a good overlap between the fluorescence emission of NaYF₄:Yb/Tm nanoparticles and the UV-visible absorption of RTA. RTA molecules were incorporated into the mesoporous silica shell and the fluorescent emission from NaYF₄:Yb/Tm nanoparticles can be absorbed by RTA molecules under NIR irradiation. NIR-initiated reactive oxygen species generation was validated by electron paramagnetic resonance spectroscopy combined with spin trapping. The results from *in-vitro* cell test show good photodynamic efficacy of this nanocomposite. All ingredients involved in this process are nontoxic, environmentally benign, and easily-available. Thus, this nanocomposite might has great potential in PDT applications.

1. Introduction

Photodynamic therapy (PDT) has emerged as a promising and noninvasive treatment for various types of cancers, involving three key components: photosensitizer (PS, also called PDT drug), light source and tissue oxygen.¹⁻³ The combination of these three components leads to the generation of different reactive oxygen species (ROS), such as singlet oxygen ($^1\text{O}_2$) through a energy-transfer process (Type II mechanism), and superoxide anion radical ($\text{O}_2^{\cdot-}$) through a electron-transfer process (Type I mechanism).⁴⁻⁶ Subsequently, ROS cause oxidative damage to biological substrates and ultimately result in cancer cell death.⁷⁻⁹ This strategy has gained wide research interest as a powerful technique for cancer treatment, due to its built-in selectivity, low systemic toxicity, minimal invasiveness as well as the possibility of its use in combination with other anticancer therapies.

Among which, PS is the key agent in PDT application and is also the research focus in the PDT-related field.¹⁰⁻¹⁶ In clinical practice, porphyrins and its derivatives, such as Photofrin (a mixture of hematoporphyrin monomers, dimers, and oligomers,) and Foscan (*m*-tetrahydroxyphenylchlorin), are the most commonly-used PDT PSs.¹⁷ However, these compounds suffer from several drawbacks: (1) tedious synthesis and purification, (2) poor water solubility, and (3) slow clearance from the body leading to possible photosensitivity after PDT treatment.¹⁸⁻²⁴ Therefore, it is still imperative to develop efficient, highly photostable, and excellent water dispersible PSs. Features desired for ideal PDT drugs, including: (1) high photochemical reactivity, that is, it can effectively produce ROS under appropriate irradiation; (2) low dark toxicity; and (3) can be excited at a wavelength in the region where tissue penetration of irradiation is at a maximum.

46 Natural products and their intricate molecular frameworks are often used as
47 starting points for drug discovery.^{11, 25-27} Riboflavin (RF), also known as vitamin B₂,
48 is an important vitamin and widely present both *in-vivo* and natural environments.²⁸⁻³¹
49 It contains a unique conjugate structure, called isoalloxazine ring, which has been
50 reported to function as an excellent natural PS for the generation of ROS, such as ¹O₂
51 and/or O₂^{•-}.³²⁻³⁴ In our previous studies, ROS generation, including highly reactive
52 hydroxyl radical (•OH), has been validated during the photosensitization process of
53 RF (**Fig. 1**). In which, RF play a dual role of photosensitizer and electron
54 mediator.³⁵⁻³⁷ All ingredients involved in this process are nontoxic, environmentally
55 benign, and easily-available. Thus, this process might have broad medical
56 implications and inspires us to probe the possibility of this vitamin working as a novel
57 PDT drug.

58 However, this idea begs the following questions: (1) the limited penetration
59 depth of the excitation wavelength of RF (<520 nm), which inflicts biological damage
60 and cannot take advantage of the optical window of tissue (700-1100 nm),³²⁻³⁹ and (2)
61 the poor photostability of RF under UV or visible irradiations.³²⁻³⁶ Nonlinear
62 processes (involving more than one photon) have been investigated as a potential
63 solution to address question (1). In this context, upconversion nanoparticles (UCNP),
64 a photo-transducer capable of converting NIR light to UV or visible light, was
65 employed as an excitation method for PDT treatment.⁴⁰⁻⁴⁶ To further underline the
66 feasibility of RF working as a PDT drug, 2',3',4',5'-tetraacetylriboflavin (RTA) was
67 designed and synthesized from RF through a esterification process of its ribose chain
68 with acetic anhydride.^{34, 47-49}

69 In this study, RTA (a photostable derivative of RF) was used as a novel PDT
70 agent. Mesoporous-silica-coated NaYF₄:Yb/Tm nanoparticles with a core/shell


71 structure were fabricated and used as drug carriers and photo-transducers for PDT
72 treatment. The emission of UCNP was used to excite the PS, as shown in **Fig. 2**. RTA
73 molecules were incorporated into the mesoporous silica shell and the fluorescent
74 emission from the UCNP can be absorbed by RTA molecules coated on their surfaces
75 under NIR irradiation. Subsequently, the excited RTA molecules interact with
76 surrounding ground-state molecular oxygen for the generation of ROS, leading to
77 oxidative damage of cancer cells.

79 **2. Experimental section**

81 *2.1. Chemicals and reagents*

82 Riboflavin (RF), 2,2,6,6-tetramethyl-4-piperidone (4-oxo-TEMP),
83 5,5-dimethyl-1-pyrroline-N-oxide (DMPO), catalase, yttrium chloride (YCl_3 , 99%),
84 ytterbium chloride (YbCl_3 , 99%), thulium chloride (TmCl_3 , 99%), octadecene (ODE),
85 ammonium fluoride (NH_4F), octadecyltrimethoxysilane (C_{18}TMS), tetraethyl
86 orthosilicate (TEOS), oleic acid, igepal CO-520 and cyclohexane were purchased
87 from Sigma-Aldrich Co. (USA). Ferrous sulfate heptahydrate ($\text{FeSO}_4 \cdot 7\text{H}_2\text{O}$), sodium
88 hydroxide (NaOH), hydrochloric acid (HCl), dimethyl sulfoxide (DMSO), acetic
89 anhydride, HPLC-grade acetic acid, and HPLC-grade ammonium acetate were
90 purchased from Shanghai Chemical Reagent Co. (China). HPLC-grade methanol was
91 purchased from Merck Inc. (Germany). Ultrapure (MilliQ Inc., USA) water
92 (resistivity of 18.2 $\text{M}\Omega\text{-cm}$) was used in the experiments. All chemicals were of
93 analytical grade (or HPLC-grade) and used without further purification.

94 RTA, a synthetic derivative of RF, was prepared through a easy-to-operated
95 esterification process of RF with acetic anhydride (**Scheme 1**).^{34, 46-48} In brief, RF (5.0
96 g) was suspended in acetic anhydride solution (50 mL), then added sulfuric acid (0.1
97 mL) to initiate the esterification reaction, and magnetic stirred at 80°C for 4 h under
98 argon atmosphere. The cooled solution was neutralized with 1.0 M NaHCO₃ (200
99 mL), extracted with CH₂Cl₂ and washed with ultrapure water. The organic layer was
100 dried with anhydrous magnesium sulfate, and evaporated under reduced pressure. The
101 raw product was further recrystallized from MeOH/H₂O (4:1; v/v) to yield pure RTA.



102
103 **Scheme. 1.** Schematic representation of synthetic procedure to obtain
104 2',3',4',5'-tetraacetylriboflavin (RTA) from riboflavin (RF).
105

106 A LTQ XL orbitrap high resolution mass spectrometry (Thermo Fisher Sci. Inc.,
107 USA), coupled with an electrospray ionization (ESI) source, was used for direct
108 injection ESI-MS analysis. Data acquisition was performed with Xcalibur 2.0
109 software (Thermo Fisher Sci. Inc., USA). The spray voltage was set to 5.0 kV,
110 capillary temperature to 280°C. The sheath and auxiliary gas flow rate (both nitrogen)
111 were set at 18 and 3 arbitrary units, respectively. Full MS scans were acquired in the
112 orbitrap analyzer in a positive mode with the resolution set to a value of 60000.
113 ¹H-NMR spectrum were collected using a Agilent 600 MHz NMR spectrometer
114 (Agilent Inc., USA). FTIR spectrum of RTA was recorded on a VERTEX 70 FT-IR
115 spectrometer (Bruker Inc., Germany) operated at a setting of 32 scans at a spectral
116 resolution of 4 cm⁻¹. **Analysis data: HR-MS (ESI) *m/z* calculated for C₂₅H₂₉N₄O₁₀**

117 [M+H]⁺ 545.1883, experimental found 545.1879. ¹H-NMR (600 MHz, DMSO-d₆,
118 ppm): 10.32 (s, 1H, Ar-NH), 7.88 (s, 1H, Ar-H), 7.72 (s, 1H, Ar-H), 5.46 (m, 1H,
119 -CHOAc), 5.33 (m, 1H, -CHOAc), 4.83 (m, 1H, -CHOAc), 4.36-4.25 (d, 2H,
120 -CH₂OAc), 4.22-4.15 (dd, 2H, -CHH), 2.50 (s, 3H, Ar-CH₃), 2.45 (s, 3H, Ar-CH₃),
121 2.38 (s, 3H, -COOCH₃), 2.18 (s, 3H, -COOCH₃), 1.98 (s, 3H, -COOCH₃), 1.60 (s, 3H,
122 -COOCH₃). FT-IR (neat KBr): ν (cm⁻¹) = 3200 (br), 3029(m), 1745 (m), 1668 (s),
123 1370 (s), 1509 (s), 1360 (s), 1231 (vs), 1171 (vs), 1035 (s), 850 (vs).

124

125 2.2. Electrochemical analysis of RTA

126 Cyclic voltammetry (CV) and differential pulse voltammetry (DPV) tests were
127 conducted in a 3-electrode system with a CHI 660C electrochemical workstation
128 (Chenhua Instrument Co., China). The system utilized glassy carbon (GC) electrode
129 as working electrode, KCl-saturated Ag/AgCl as reference electrode, platinum wire as
130 counter electrode. Before each test, the GC electrode (d = 3 mm) was polished with
131 0.3- and 0.05- μ m alumina powder in succession, and sonicated in water for 30
132 seconds. The electrolyte, consisted of 100 μ M RTA in 100 mM PBS (pH 7.0), was
133 deoxygenated by nitrogen prior to the electrochemical tests. All experiments were
134 conducted at ambient temperature of 25°C.

135

136 2.3. Synthesis of mesoporous silica-coated NaYF₄:Yb/Tm nanoparticles

137 NaYF₄:Yb/Tm nanoparticles were fabricated and used as photo-transducers in
138 this study. NaYF₄:Yb/Tm nanocrystals with uniform size distribution were
139 synthesized via an efficient and user-friendly method.^{41,42} NaYF₄:Yb(18%)/Tm(2%)
140 nanocrystals were synthesized following a protocol that was reported previously.^{16,41}
141 YCl₃ (0.8 mmol), YbCl₃ (0.18 mmol), and TmCl₃ (0.02 mmol) were mixed with 12

142 mL oleic acid and 15 mL octadecene (ODE) in a 50 mL flask. The solution was
143 heated to 160°C to form a homogeneous solution, and then cooled to ambient
144 temperature (25°C). A 10 mL methanol solution containing NaOH (2.5 mmol) and
145 NH₄F (4 mmol) was slowly added into the flask and stirred for 30 min. The solution
146 was slowly heated to remove methanol, degassed at 100°C for 10 min, and then
147 heated to 300°C and maintained for 2.0 h under argon protection. After the solution
148 was cooled naturally, nanocrystals were precipitated from the solution with ethanol
149 and washed with ethanol/water (1:1 v/v) three times.

150 Porous silica-coated NaYF₄:Yb/Tm nanoparticles were further achieved
151 successfully by one pot facile synthetic process.³⁹ Octadecyltrimethoxysilane
152 (C₁₈TMS) was used as soft template, which has been used for preparing hydrophobic
153 coatings and self-assembled monolayers. Briefly, CO-520 (1.0 mL), cyclohexane (6.0
154 mL) and NaYF₄:Yb/Tm nanocrystal solution in cyclohexane (40 mL, 0.01 M) were
155 mixed and stirred for 60 min. Then, 1.0 mL ammonia (28 wt%) was added into the
156 previous solution and sonicated for 30 min until a transparent emulsion was formed.
157 The mixture solution of 120 μL TEOS and 50 μL octadecyltrimethoxysilane
158 (C₁₈TMS) was then added into the previous solution. Finally, the solution was stirred
159 for 48 h at a speed of 800 rpm at ambient temperature of 25°C. Silica-coated
160 NaYF₄:Yb/Tm nanoparticles were collected by centrifugation after precipitation by
161 adding acetone, washed with ethanol three times and finally dried at 60°C for 10 h.
162 The as-prepared sample was calcinated at 500°C in static air with a heating rate of
163 1.0°C/min and a dwelling time of 2.0 h.

164 Mesoporous-silica-coated NaYF₄:Yb/Tm nanoparticles (20 mg) were soaked in
165 aqueous solutions of PSs (RTA or RF, 50 mL, 10 μg/mL) for 24 h at ambient
166 temperature (25°C). The nanoparticles were then collected by centrifugation (5000 g,

167 5 min) and washed with phosphate buffer saline solution (PBS, 0.02 M, pH=7.40).
168 Initial and residual concentrations of PSs were analyzed using a high performance
169 liquid chromatography system (HPLC-1100, Agilent Inc., USA) equipped with a
170 VWD detector and a Hypersil ODS column. A mixture of methanol and water (30:70,
171 v/v) was used as the isocratic mobile phase with 0.1% acetic acid in water. The flow
172 rate was set at 1.0 mL/min, the UV detector was set at 360 nm, and the column
173 temperature was set at 30°C.

174 The morphology and size of the as-prepared samples were investigated by
175 transmission electron microscopy (TEM, JEOL 3010, JEOL Co., Japan). UV-visible
176 absorption spectra were performed using a UV-visible spectrometry (UV-2450,
177 Shimadzu Co., Japan). The spectra were collected from 200 nm to 800 nm by an
178 increment of 0.5 nm. All measurements were performed in standard 10 mm quartz
179 cuvettes. Excitation–emission matrix fluorescence spectroscopic analysis was
180 performed using a luminescence spectrometry (LS-55, Perkin-Elmer Co., USA)
181 equipped with a 980 nm excitation source. Fluorescence spectra were collected with
182 subsequent scanning emission spectra from 200 to 800 nm by an increment of 0.5 nm
183 under the 980 nm-excitation.

184 185 *2.4. Photostability analysis of RTA*


186 The photostabilities of RTA and RF under both visible and NIR irradiation were
187 evaluated in aqueous solutions (pH=7.0). A 50-W Xe-arc lamp (XD-300, Nanjing
188 Yanan Co., China) equipped with an UV-cutoff (>400 nm) was used as visible light
189 source and a 980 nm NIR laser (MDL-980, Changchun New industries
190 optoelectronics tech. Co., China) was used as NIR light source. Samples were

191 irradiated, and aliquots were removed and analyzed at given time intervals (10 min).
192 The light dependence processes were monitored and analyzed using both high
193 performance liquid chromatography (HPLC-1100, Agilent Inc., USA) and UV-visible
194 spectrometry (UV-2450, Shimadzu Co., Japan).

196 2.5. ROS detection using electron paramagnetic resonance spectroscopy

197 EPR spectra were obtained using a JEOL JES-FA200 EPR spectrometer (JEOL
198 Co., Japan) with a 500-W Xe-arc lamp equipped with an UV-cutoff (>400 nm) as
199 visible-light source and a 980-nm laser with an output power of 1000 mW as a
200 near-infrared (NIR) light source. Spectrometer with X-band microwave frequency of
201 9.072 GHz, microwave power of 2.02 mW, spectral window of 100 G, and
202 modulation amplitude of 1.00 G was used at ambient temperature of 25°C.
203 4-oxo-TEMP was used to detect $^1\text{O}_2$, and DMPO was utilized to measure $\text{O}_2^{\cdot-}$ and
204 $\cdot\text{OH}$.^{35, 36, 50-53}


205 $^1\text{O}_2$ was detected with the EPR method using 4-oxo-TEMP as a spin-trapping
206 reagent (Reaction 1).^{35, 50} Solutions of RTA were prepared in ultrapure water. Under
207 visible irradiation, the incubation of RTA at 100 μM with the spin-trapping agent
208 4-oxo-TEMP of 100 mM resulted in the formation of a adducts. 200 μL of the freshly
209 prepared mixture was added to a quartz EPR tube and illuminated for 0, 1.0, 2.0, 3.0,
210 4.0, and 5.0 min before recording the EPR spectra. Under NIR-irradiation, the
211 incubation of RTA/UCNP (5 mg/mL) with the spin-trapping agent 4-oxo-TEMP of
212 100 mM resulted in the formation of the adducts of 4-oxo-TEMP/ $^1\text{O}_2$. 200 μL of the
213 freshly prepared mixture was added to a quartz EPR tube and illuminated for 10 min
214 before recording the EPR spectra. The generation of $^1\text{O}_2$ was detected as an EPR
215 signal, because 4-oxo-TEMPO is formed by the reaction of $^1\text{O}_2$ with 4-oxo-TEMP.



216


217 DMPO was used as a spin-trapping agent for the detection of $O_2^{\bullet -}$ (Reaction 2).^{35,}

218 ^{36,50} Solutions of RTA were prepared in DMSO. Under visible irradiation, the
 219 incubation of 100 μ M RTA with 100 mM spin-trapping agent DMPO resulted in the
 220 formation of the radical adducts. 200 μ L of the freshly prepared mixture was added to
 221 a quartz EPR tube and illuminated for 0, 0.5, 1.0, 1.5, and 2.0 min before recording
 222 the EPR spectra. Under NIR-irradiation, the incubation of RTA/UCNP (5 mg/mL)
 223 with 100 mM spin-trapping agent DMPO resulted in the formation of the radical
 224 adducts. 200 μ L of the freshly prepared mixture was added to a quartz EPR tube and
 225 illuminated for 10 min before recording the EPR spectra.



226

227 DMPO was also used as a spin-trapping agent for the detection of HO^{\bullet} (Reaction
 228 3).^{36, 51, 52} Solutions were prepared in ultrapure water. Under visible irradiation, the
 229 incubation of RTA (100 μ M) and $FeSO_4$ (10 μ M) with 100 mM spin-trapping agent
 230 DMPO resulted in the formation of the radical adducts. Then, 200 μ L of the freshly
 231 prepared mixture was added to a quartz EPR tube and illuminated for 0, 1.0, 2.0, and
 232 3.0 min before recording the EPR spectra. Under NIR-irradiation, the incubation of
 233 RTA/UCNP (5 mg/mL) and $FeSO_4$ (2 μ M) with 100 mM spin-trapping agent DMPO
 234 resulted in the formation of the radical adducts. Then, 200 μ L of the freshly prepared
 235 mixture was added to a quartz EPR tube and illuminated for 10 min before recording
 236 the EPR spectra.



237

238

239

2.6. Cell culture and *in-vitro* PDT test

240 *In-vitro* cytotoxicity assays were further performed using the human breast
241 cancer cell line MDA-MB-231 from the American Type Culture Collection (ATCC).
242 MDA-MB-231 cells were cultured in RPMI 1640 medium, supplemented with 10%
243 fetal bovine serum and 2 mM L-glutamine at 37°C using a humidified 5% CO₂
244 incubator. The MDA-MB-231 cells were seeded onto 96-well plates at 2.0×10³ cells
245 per well and further incubated for 24 h. The culture medium was then replaced with
246 100 μL of freshly prepared culture medium containing either free PS or PS/UCNP at
247 different concentrations.

248 Cells were treated with free RF, RTA, RF/UCNP or RTA/UCNP composites and
249 incubated for 24 h and then exposed to visible or 980 nm-NIR irradiation. All cells
250 were then incubated for another 48 h at 37°C and evaluated by MTT viability assay.
251 For MTT assay, MDA-MB-231 cancer cells were collected and diluted to a cell
252 density of 1×10⁵/mL in complete medium, and then seeded into 96-well plates (100
253 μL/well). After being cultured for 24 h, the nanoparticles with different concentrations
254 (0.625, 1.25, 2.5, and 5.0 mg/mL) with and without PS were added to the cells and the
255 cells were incubated for 24 h at 37°C. The exposure time of NIR-irradiation was
256 divided into several sections (2 min per section) to avoid the over-heating possibility.
257 The cells were then incubated at 37°C for 48 h. The cell viability was measured by
258 MTT assay (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazoliumbromide) and
259 expressed as a percentage of the control.

3. Results and Discussion

3.1. Electrochemical characteristics of RTA

The known ability of isoalloxazine ring to act as an excellent PS has been supposed to play a key role in the generation of $^1\text{O}_2$ or $\text{O}_2^{\cdot-}$. In our previous study, RF has been reported to play a dual role of excellent PS and effective electron mediator in the process of $\cdot\text{OH}$ generation.^{35, 36} Some PSs have been shown to produce different kind ROS, and synergistic effects of $^1\text{O}_2$ and $\cdot\text{OH}$ on PDT treatment has been proposed.¹⁷ However, RF is susceptible to photodegradation, likely due to the instability of the ribose chain. Chemical modification of the ribose chain of the molecule is highly desired, and can improve the yield and lifetime of the triplet state and result in a more photostable derivative.^{34, 47-49} RTA was synthesized through a easy-to-operated esterification process of RF with acetic anhydride. The electron shuttling capacity of RF as a redox-active molecule paly a key role in the generation of $\text{O}_2^{\cdot-}$ or $\cdot\text{OH}$. Thus, electrochemical characterization of RTA and RF were firstly conducted to analysis of their oxidation-reduction potentials.

The sterile glassy carbon electrodes were exposed to 0.05 mM RF. CV analysis was performed at a scan rate of 100 mV/s. The potential difference between oxidation and reduction peaks was 58 mV and the centers of the reversible voltammetric peaks were at -0.40V (**Fig. 3A**). These results show the oxidation-reduction process of RF is reversible and RF could be used as a mediator in electron transfer process. To test the redox property of RTA, CV experiments were conducted in RTA solution. Compared to the blank electrolyte (PBS solution), RTA shows a pair of obvious reversible redox peaks with potential difference between oxidation and reduction peaks was 49 mV, and the centers of the reversible voltammetric peaks were at -0.37 V. The redox peaks

285 of RTA were more positive than that of RF, which was consistent with DPV results
286 (**Fig. 3B**). The DPV results show that the redox potential of RTA was larger than that
287 of RF by 30 mV. These results indicate that RTA was more easily to be reduced.
288 Additionally, the peak separation of RTA was also smaller, suggesting that RTA was
289 more electrochemically reversible than RF. These results demonstrate that RTA was
290 successfully synthesized from RF and its electrochemical properties were improved
291 after the modification.

293 *3.2. Characteristics of NaYF₄:Yb/Tm upconversion nanoparticles*

294 TEM analysis was used to examine the morphology of the UCNP nanoparticles.
295 The results clear show that the nanoparticles were discrete and uniform with an
296 average diameter of 30 and 50 nm for NaYF₄:Yb/Tm (**Fig. 4A**) and porous
297 silica-coated NaYF₄:Yb/Tm (**Fig. 4B**), respectively. Brunauer–Emmet–Teller (BET)
298 analysis reveal mesoporous structure of silica-coated NaYF₄:Yb/Tm with an average
299 pore-size distribution of 2.30 nm and a specific surface area of 680 m²/g.
300 Mesoporous-silica-coated NaYF₄:Yb/Tm nanoparticles (100 mg) were soaked in PS
301 aqueous solution (RF or RTA, 100 mL, 0.1 mM) for 24 h at ambient temperature of
302 25°C. The nanoparticles were then collected by centrifugation and washed with PBS
303 solution (0.02 M, pH=7.4). Concentrations of PS solutions (RTA or RF) were
304 determined using HPLC method and the amount of adsorbed into the mesoporous
305 silica was about 2.0 wt%.

307 *3.3. Emission spectrum analysis of NaYF₄:Yb/Tm nanoparticles and absorbance 308 spectrum analysis of RTA*

309 The luminescent spectrum of NaYF₄:Yb/Tm nanoparticles and the UV-visible
310 absorption spectrum of the RTA and RF solutions were further analyzed. The

311 luminescence spectrum of the mesoporous silica-coated NaYF₄:Yb/Tm upon
312 NIR-irradiation (980 nm) is shown in Fig. 5A. The dominant emissions are located at
313 345, 360, 451, and 476 nm. As shown in Fig. 5B, there is a good overlap between the
314 fluorescence emission of NaYF₄:Yb/Tm nanoparticles and the UV-visible absorption
315 of RTA and RF solutions (main peaks located at 372 and 450 nm). It is envisaged that
316 the PS (RTA or RF) can be aborted and activated by the UCNP to produce ROS and
317 kill cancer cells when exposed to NIR irradiation.

319 3.4. Photostability analysis of RTA

320 Qualitative evaluation of the photostabilities of RTA and RF were performed
321 under visible or NIR (980 nm, 500 mw) irradiation. Initial and residual concentrations
322 of RTA and RF were analyzed using HPLC. Free RF in solution was degraded
323 completely after one hour of visible irradiation, while RTA was degraded only 20%
324 under similar conditions. Compared with visible irradiation, both free RTA and RF,
325 and in the form of PS/UCNP nanocomposites exhibit an appreciable photostability
326 under NIR irradiation, as shown in **Fig. 6**. These results indicate that the RTA
327 molecule in the form of RTA/UCNP nanocomposite has a good photostability under
328 NIR irradiation, and could used as a potential candidate of PS for PDT applications.

330 3.5. Analysis of ROS using electron paramagnetic resonance spectroscopy

331 ROS generation during the NIR-triggered photosensitization process RTA was
332 analyzed using EPR spectroscopy combined with spin trapping. Solution of
333 RTA/UCNP (5 mg/mL) with DMPO (100 mM) was prepared in ultrapure water
334 (pH=3.0). 4-oxo-TEMP was used to detect ¹O₂, and DMPO was utilized to measure
335 O₂^{•-} and •OH.^{51, 52} 200 μL of this freshly prepared mixture was added to a quartz EPR

336 tube and illuminated for 5.0 min before recording the EPR spectra. The specific
337 signals of 4-oxo-TEMP/ $^1\text{O}_2$ were produced by $^1\text{O}_2$ generated from photoexcited RTA
338 (**Fig. 7A**). The spectrum is composed of a triplet of lines, with a peak height ratio of
339 1:1:1, with parameters including hyperfine constants, $a_{\text{N}}=16.30$ G and a
340 g -value=2.0055. These parameters exactly matched with accurate EPR spectrum
341 simulation of 4-oxo-TEMP/ $^1\text{O}_2$. $\text{O}_2^{\cdot-}$ is sensitive to the presence of proton and its
342 lifetime is very short in protic solvents.^{35,36} Thus, it is difficult to detect $\text{O}_2^{\cdot-}$ in protic
343 solvent and an aprotic solvent of DMSO was used in this study to facilitate $\text{O}_2^{\cdot-}$
344 detection.^{51,53} The hyperfine splitting constants for DMPO/ $\text{O}_2^{\cdot-}$ were $a_{\text{N}}=12.80$ G;
345 $a_{\text{H}}^{\beta}=10.41$ G; $a_{\text{H}}^{\gamma}=1.35$ G; $g=2.0021$ (**Fig. 7B**). An accurate EPR spectrum simulation
346 of DMPO/ $\text{O}_2^{\cdot-}$ has also been performed.

347 On the basis of the analysis of both $\text{O}_2^{\cdot-}$ and $^1\text{O}_2$, we further examined the
348 feasibility of NIR-initiated $\cdot\text{OH}$ generation of RTA solution in the presence of
349 dissolved-iron. Solution of RTA/UCNP (5 mg/mL) and FeSO_4 (5 μM) with DMPO
350 (100 mM) was prepared in acidic water (pH=3.0). Upon exposure to NIR irradiation,
351 a major radical/DMPO adduct was formed and assigned to DMPO/ $\cdot\text{OH}$. The
352 hyperfine splitting constants for DMPO/ $\cdot\text{OH}$ were $a^{\text{H}}=a^{\text{N}}=14.96$ G and a
353 g -value=2.0050 (**Fig. 7C**). Among the signals for DMPO/ $\cdot\text{OH}$ (1:2:2:1), a weak EPR
354 signal was composed of a triplet of lines with a peak height ratio of 1:1:1. There is a
355 signal of oxidized DMPO (DMPOX) in the EPR spectra. Similar results of ROS
356 generation were obtained with RF/UCNP solution under NIR irradiation.

358 3.6. *In-vitro* PDT activity of RTA/UCNP nanocomposites

359 As designed, the NIR-triggered release of ROS from RTA/UCNP
360 nanocomposites was deemed to exhibit the spatio-temporal controlled anticancer

361 effects. Therefore, the therapeutic potential of RTA/UCNP composite was evaluated
362 *in-vitro* using the human breast cancer cell. Cells with free RTA or RF (10 $\mu\text{g}/\text{mL}$)
363 were exposed to a 50-W Xe-arc lamp equipped with an UV-cutoff (>400 nm). The
364 cell viability with different exposure time to visible irradiation (5, 10, 20, and 30 min)
365 indicated that the cell viability decreased with the exposure time under visible
366 irradiation, suggesting an increased amount of ROS produced by the PS (RTA or RF).
367 Normal incubated cells was used as control (Control-1). Cells incubated without
368 visible irradiation show that both RF (Control-2) and RTA (Control-3) are nontoxic
369 and biocompatible. Cells of control-4 were incubated under visible irradiation without
370 adding any PS. RTA has a much better PDT effect than RF, which can be attributed to
371 the improved photostability of RTA. The results of the control tests show that PS and
372 visible irradiation were both required.

373 **Fig. 8A** shows the effect of exposure time to NIR irradiation on the cell viability
374 in the presence of RTA/UCNP or RF/UCNP (5 mg/mL). Cells cultured with
375 PS/UCNP were exposed to a 980 nm-NIR-laser with an output power of 500 mW.
376 The cell viability of cancer cells clearly decreased with increasing irradiation time.
377 Control experiments with NIR irradiation in the absence of PS/UCNP also showed
378 that NIR irradiation alone did not initiate cell death. **Fig. 8B** showed that the viability
379 of cells incubated with the amount of RTA/UCNP (0.625, 1.25, 2.5, and 5 mg/mL)
380 exposed to NIR irradiation for 30-min was significantly lower as compared to the
381 nanoparticles without RTA/UCNP (Control-1) or without NIR irradiation (Control-2).
382 Similar results were obtained with RF/UCNP solution under NIR irradiation.

383 **Fig. 8C** shows the effect of Fe^{2+} on the cell viability. At a low concentration
384 range (0-1.0 $\mu\text{g}/\text{mL}$), the cell viability decreased with an increase of Fe^{2+}
385 concentration. Interestingly, the adding of Fe^{2+} facilitates the generation of $\bullet\text{OH}$, and

386 results in a increase of phototoxicity. However, with Fe^{2+} concentration further
387 increased, the cell viability increased with increasing Fe^{2+} concentration.

388

389 **4. Conclusions**

390

391 In summary, a novel NIR-light-triggered PDT nanosystem has been developed using
392 an old vitamin (VB_2) integrated with the upconversion nanotechnology.
393 Mesoporous-silica-coated $\text{NaYF}_4:\text{Yb}/\text{Tm}$ nanoparticles were successfully fabricated,
394 which played a dual role of drug carrier and photo transducer. Chemical
395 modification of this old vitamin was performed through a easy-to-operated
396 esterification process to improve its photostability. This nanoplatform has some
397 desired features for an ideal PDT drug, including: (1) high water-solubility; (2)
398 excellent photochemical reactivity to produce reactive oxygen species; (3) low dark
399 toxicity; and (4) can be excited at NIR region where tissue penetration of irradiation is
400 at a maximum. The results of *in-vitro* cell experiment demonstrate that RTA/UCNP
401 nanocomposite of the proposed design has great potential in PDT application.

402 **Acknowledgements**

403 The authors wish to thank the National Science Foundation of China (No.21207031,
404 No.21471043), the China Postdoctoral Science Foundation (No. 2016M592049), and
405 the Key Laboratory of Urban Pollutant Conversion, Chinese Academy of Sciences
406 (No. KF201603) for the support of this study.

407

408

409

410 **References**

- 411 1 D. E. Dolmans, D. Fukumura and R. K. Jain, Photodynamic therapy for cancer,
412 *Nat. Rev. Cancer*, 2003, **3**, 380-387.
- 413 2 R. S. Balaban, S. Nemoto and T. Finkel, Mitochondria, oxidants, and aging, *Cell*,
414 2005, **120**, 483-495.
- 415 3 K. Ishikawa, K. Takenaga, M. Akimoto, N. Koshikawa, A. Yamaguchi, H.
416 Imanishi, K. Nakada, Y. Honma and J. Hayashi, ROS-generating mitochondrial
417 DNA mutations can regulate tumor cell metastasis, *Science*, 2008, **320**, 661-664.
- 418 4 W. M. Sharman, C. M. Allen and J. E. van Lier, Photodynamic therapeutics:
419 basic principles and clinical applications, *Drug Discov. Today*, 1999, **4**, 507-517.
- 420 5 P. Mroz, A. Pawlak, M. Satti, H. Lee, T. Wharton, H. Gali, T. Sarna and M. R.
421 Hamblin, Functionalized fullerenes mediate photodynamic killing of cancer cells:
422 Type I versus Type II photochemical mechanism, *Free Radical Bio. Med.*, 2007,
423 43, 711-719.
- 424 6 Y. Arenas, S. Monro, G. Shi, A. Mandel, S. McFarland and L. Lilge,
425 Photodynamic inactivation of *Staphylococcus aureus* and methicillin-resistant
426 *Staphylococcus aureus* with Ru(II)-based type I/type II photosensitizers,
427 *Photodiagn. Photodyn. Ther.*, 2013, **10**, 615-625.
- 428 7 M. Ochsner, Photophysical and photobiological processes in the photodynamic
429 therapy of tumors, *J. Photochem. Photobiol. B Biol.*, 1997, **39**, 1-18.
- 430 8 L. Li, G. Ishdorj and S. B. Gibson, Reactive oxygen species regulation of
431 autophagy in cancer: Implications for cancer treatment, *Free Radical Bio. Med.*,
432 2012, **53**, 1399-1410.

- 433 9 F. Cieplik, A. Späth, J. Regensburger, A. Gollmer, L. Tabenski, K. Hiller, W.
434 Bäumlér, T. Maisch and G. Schmalz, Photodynamic biofilm inactivation by
435 SAPYR-An exclusive singlet oxygen photosensitizer, *Free Radical Bio. Med.*,
436 2013, **65**, 477-487.
- 437 10 Y. Yamakoshi, N. Umezawa, A. Ryu, K. Arakane, N. Miyata, Y. Goda, T.
438 Masumizu and T. Nagano, Active oxygen species generated from photoexcited
439 fullerene (C₆₀) as potential medicines: O₂^{•-} versus ¹O₂, *J. Am. Chem. Soc.*, 2003,
440 **125**, 12803-12809.
- 441 11 A. Montazerabadi, A. Sazgarnia, M. H. Bahreyni-Toosi, A. Ahmadi, A.
442 Shakeri-Zadeh and A. Aledavood, Mitoxantrone as a prospective photosensitizer
443 for photodynamic therapy of breast cancer, *Photodiagn. Photodyn. Ther.*, 2012, **9**,
444 46-51.
- 445 12 A. Nadhman, S. Nazir, M. I. Khan, S. Arooj, M. Bakhtiar, G. Shahnaz and M.
446 Yasinzai, PEGylated silver doped zinc oxide nanoparticles as novel
447 photosensitizers for photodynamic therapy against Leishmania, *Free Radical Bio.*
448 *Med.*, 2014, **77**, 230-238.
- 449 13 W. J. Yan, Q. Wang, C. H. Yuan, F. Wang, Y. Ji, F. Dai, X. L. Jin and B. Zhou,
450 Designing piperlongumine-directed anticancer agents by an electrophilicity-based
451 prooxidant strategy: A mechanistic investigation, *Free Radical Bio. Med.*, 2016,
452 **97**, 109-123.
- 453 14 M. Rajendran, Quinones as photosensitiser for photodynamic therapy: ROS
454 generation, mechanism and detection methods, *Photodiagn. Photodyn. Ther.*,

- 455 2016, **13**, 175-187.
- 456 15 C. S. Lee, W. Park, Y. U. Jo and K. Na, A charge-switchable, four-armed
457 polymeric photosensitizer for photodynamic cancer therapy, *Chem. Commun.*,
458 2014, **50**, 4354-4357.
- 459 16 F. Xu, L. Ding, W. Tao, X. Z. Yang, H. S. Qian and R. S. Yao,
460 Mesoporous-silica-coated upconversion nanoparticles loaded with vitamin B₁₂ for
461 near-infrared-light mediated photodynamic therapy, *Materials Lett.*, 2016, **167**,
462 205-208.
- 463 17 J. M. Dąbrowski, L. G. Arnaut, M. M. Pereira, K. Urbańska, S. Simões, G.
464 Stochel and L. Cortes, Combined effects of singlet oxygen and hydroxyl radical
465 in photodynamic therapy with photostable bacteriochlorins: Evidence from
466 intracellular fluorescence and increased photodynamic efficacy *in vitro*, *Free
467 Radical Bio. Med.*, 2012, **52**: 1188-1200.
- 468 18 X. Chen, L. Hui, D. A. Foster and C. M. Drain, Efficient synthesis and
469 photodynamic activity of porphyrin-saccharide conjugates: Targeting and
470 incapacitating cancer cells, *Biochemistry*, 2004, **43**, 10918-10929.
- 471 19 I. Lanzo, N. Russo and E. Sicilia, First-principle time-dependent study of
472 magnesium-containing porphyrin-like compounds potentially useful for their
473 application in photodynamic therapy, *J. Phys. Chem. B*, 2008, **112**, 4123-4130.
- 474 20 J. F. Lovell, M. W. Chan, Q. C. Qi, J. Chen and G. Zheng, Porphyrin FRET
475 acceptors for apoptosis induction and monitoring, *J. Am. Chem. Soc.*, 2011, **133**,
476 18580-18582.
- 477 21 X. C. Zhu, W. T. Lu, Y. Z. Zhang, A. Reed, B. Newton, Z. Fan, H. T. Yu, P. C.


- 478 Ray and R. M. Gao, Imidazole-modified porphyrin as a pH-responsive sensitizer
479 for cancer photodynamic therapy, *Chem. Commun.*, 2011, **47**, 10311-10313.
- 480 22 T. C. Lei, G. F. Glazner, M. Duffy, L. Scherrer, S. Pendyala, B. H. Li, X. L.
481 Wang, H. W. Wang and Z. Huang, Optical properties of hematoporphyrin
482 monomethyl ether (HMME), a PDT photosensitizer, *Photodiagn. Photodyn. Ther.*,
483 2012, **9**, 232-242.
- 484 23 R. Dosselli, C. Tampieri, R. Ruiz-González, S. De Munari, X. Ragàs, D.
485 Sánchez-García, M. Agut, S. Nonell, E. Reddi and M. Gobbo, Synthesis,
486 characterization, and photoinduced antibacterial activity of porphyrin-type
487 photosensitizers conjugated to the antimicrobial peptide apidaecin 1b, *J. Med.*
488 *Chem.*, 2013, **56**, 1052-1063.
- 489 24 E. Alves, M. A. F. Faustino, M. G. P. M. S. Neves, Â. Cunha, H. Nadais and A.
490 Almeida, Potential applications of porphyrins in photodynamic inactivation
491 beyond the medical scope, *J. Photochem. Photobiol., C: Photochem. Rev.*, 2015,
492 **22**, 34-57.
- 493 25 T. Rodrigues, D. Reker, P. Schneider and G. Schneider, Counting on natural
494 products for drug design, *Nat. Chem.*, 2016, **8**, 531-541; 2016.
- 495 26 T. A. Shell and D. S. Lawrence, A new trick (hydroxyl radical generation) for an
496 old Vitamin (B₁₂), *J. Am. Chem. Soc.*, 2011, **133**, 2148-2150.
- 497 27 T. A. Shell, J. R. Shell, Z. L. Rodgers and D. S. Lawrence, Tunable visible and
498 near-IR photoactivation of light-responsive compounds by using fluorophores as
499 light-capturing antennas, *Angew. Chem. Int. Ed.*, 2014, **53**, 875-878.

- 500 28 H. Canstein, J. Ogawa, S. Shimizu and J. R.Lloyd, Secretion of flavins by
501 *Shewanella* species and their role in extracellular electron transfer, *Appl. Environ.*
502 *Microb.*, 2008, **7**, 615-623.
- 503 29 E. Marsili, D. B. Baron, I. D. Shikhare, D. Coursolle, J. A. Gralnick and D. R.
504 Bond, *Shewanella* secretes flavins that mediate extracellular electron transfer,
505 *Proc. Natl. Acad. Sci. USA*, 2008, **105**, 3968-3973.
- 506 30 S. Sanudo-Wilhelmy, L. S. Cutter, R. Durazo, E. A. Smail, L. Gomez-Consarnau,
507 E. A. Webb, M. G. Prokopenko, W. M. Berelson and . Karl, multiple B-vitamin
508 depletion in large areas of the coastal ocean, *Proc. Natl. Acad. Sci. USA*, 2009,
509 **109**,14041-14045.
- 510 31 S. Babanova, O. Bretschger, J. Roy, A. Cheung, K. Artyushkova and P.
511 Atanassov, Innovative statistical interpretation of *Shewanella oneidensis*
512 microbial fuel cells data *Phys. Chem. Chem. Phys.*, 2014,**16**, 8956-8969.
- 513 32 Y. Barbieri, W. A. Massad, D. J. Diaz, J. Sanz, F. Amat-Guerri and N. A. Garcia,
514 photodegradation of bisphenol A and related compounds under natural-like
515 conditions in the presence of riboflavin: Kinetics, mechanism and photoproducts,
516 *Chemosphere*, 2008, **73**, 564-571.
- 517 33 E. Haggi, S. Bertolotti and N. A. Garcia, Modelling the environmental
518 degradation of water contaminants. Kinetics and mechanism of the
519 riboflavin-sensitized-photo oxidation of phenolic compounds, *Chemosphere*,
520 2004, **5**, 1501-1507.
- 521 34 C. K. Remucal and K. McNeill, Photosensitized amino acid degradation in the

- 522 presence of riboflavin and its derivatives, *Environ. Sci. Technol.*, 2011, **45**,
523 5230-5237.
- 524 35 F. Xu, X. N. Song, G. P. Sheng, H. W. Luo, W. W. Li, R. S. Yao and H. Q. Yu,
525 Sunlight-mediated degradation of methyl orange sensitized by riboflavin: Roles
526 of reactive oxygen species, *Sep. Purif. Technol.*, 2015, **142**, 18-24.
- 527 36 F. Xu, X. N. Song, G. P. Sheng, H. W. Luo, W. W. Li, R. S. Yao and H. Q. Yu,
528 Vitamin B₂-initiated hydroxyl radical generation under visible light in the
529 presence of dissolved iron, *ACS Sustainable Chem. Eng.*, 2015, **3**, 1756-1763.
- 530 37 Y. Suzuki, Y. Kitatsuji, T. Ohnuki and S. Tsujimura, Flavin mononucleotide
531 mediated electron pathway for microbial U(VI) reduction, *Phys. Chem. Chem.*
532 *Phys.*, 2010, **12**, 10081-10087.
- 533 38 E. Kosarieh, S. S. Khavas, A. Rahimi, N. Chiniforush and N. Gutknecht,
534 The comparison of penetration depth of two different photosensitizers in root anal
535 s with and without smear layer: An in vitro study, *Photodiagn. Photodyn. Ther.*,
536 2016, **13**, 10-14.
- 537 39 S. Kishimoto, M. Bernardo, K. Saito, S. Koyasu, J. B. Mitchell, P. L. Choyke and
538 M. C. Krishn, Evaluation of oxygen dependence on in vitro and in vivo
539 cytotoxicity of photoimmunotherapy using IR-700-antibody conjugates, *Free*
540 *Radical Bio. Med.*, 2015, **85**, 24-32.
- 541 40 D. Gao, R. R. Agayan, H. Xu, M. A. Philbert and R. Kopelman, Nanoparticles for
542 two-photon photodynamic therapy in living cells, *Nano Lett.*, 2006, **6**, 2383-2386.
- 543 41 H. S. Qian, H. C. Guo, P. C. L. Ho, R. Mahendran and Y. Zhang,

- 544 Mesoporous-silica-coated up-conversion fluorescent nanoparticles for
545 photodynamic therapy, *Small*, 2009, **5**, 2285-2290.
- 546 42 B. B. Ding, H.Y. Peng, H. S. Qian, L. Zheng and S. H. Yu, Unique upconversion
547 core-shell nanoparticles with tunable fluorescence synthesized by a sequential
548 growth process, *Adv. Mater. Interfaces*, 2016, **3**, 1500649.
- 549 43 P. Zhang, W. Steelant, M. Kumar and M. Scholfield, Versatile photosensitizers
550 for photodynamic therapy at infrared excitation, *J. Am. Chem. Soc.*, 2007, **129**,
551 4526-4527.
- 552 44 A. V. Kachynski, A. Pliss, A. N. Kuzmin, T. Y. Ohulchanskyy, A. Baev, J. Qu
553 and P. N. Prasad, Photodynamic therapy by in situ nonlinear photon conversion,
554 *Nat. Photon.*, 2014, **8**, 455-461.
- 555 45 G. F. Wang, Q. Peng and Y. D. Li, Lanthanide-doped nanocrystals: synthesis,
556 optical-magnetic properties, and applications, *Acc. Chem. Res.*, 2011, **44**,
557 322-332.
- 558 46 L. Z. Zhao, J. J. Peng, Q. Huang, C. Y. Li, M. Chen, Y. Sun, Q. N. Lin, L. Y. Zhu
559 and F. Y. Li, Near-infrared photoregulated drug release in living tumor tissue via
560 yolk-shell upconversion nanocages, *Adv. Funct. Mater.*, 2014, **24**, 363-371.
- 561 47 E. C. Smith and D. E. Metzler, Photochemical degradation of riboflavin, *J. Am.*
562 *Chem. Soc.*, 1963, **85**, 3285-3287.
- 563 48 P. F. Heelis, The photophysical and photochemical properties of flavins
564 (Isoalloxazines), *Chem. Soc. Rev.*, 1982, **11**, 15-39.
- 565 49 R. A. Larson, P. L. Stackhouse and T. O. Crowley, Riboflavin tetraacetate: A


- 566 potentially useful photosensitizing agent for the treatment of contaminated waters,
567 *Environ. Sci. Technol.*, 1992, **26**, 1792-1798.
- 568 50 S. S. Kumar, T. P. A. Devasagayam, B. Bhushan and N. C. Verma, Scavenging of
569 reactive oxygen species by chlorophyllin: an ESR study, *Free Radic. Res.*, 2001,
570 **35**, 563-574.
- 571 51 P. Pieta, A. Petr, W. Kutner and L. Dunsch, In situ ESR spectroscopic evidence
572 of the spin-trapped superoxide radical, $O_2^{\cdot-}$, electrochemically generated in
573 DMSO at room temperature, *Electrochim. Acta.*, 2008, 53, 3412-3415.
- 574 52 J. L. Roberts, M. M. Morrison and D. T. Sawyer, Base-induced generation of
575 superoxide ion and hydroxyl radical from hydrogen peroxide, *J. Am. Chem. Soc.*,
576 1978, **100**, 329-330.
- 577 53 M. J. Burkitt and R. P. Mason, Direct evidence for in vivo hydroxyl-radical
578 generation in experimental iron overload: an ESR spin-trapping investigation,
579 *Proc. Natl. Acad. Sci. USA.*, 1991, **88**, 8440-8444.



580
581
582 **Fig. 1.** Schematic illustration of RF-initiated ROS generation under visible irradiation

583 (RF: Riboflavin; ISC: Intersystem Crossing).

584



585

586

587


588

589

590

591

Fig. 2. Schematic illustration of the PS/UCNP nanoplatform for PDT and Proposed NIR-triggered ROS generation leading to oxidative damage of cancer cells, RTA (2',3',4',5'-tetraacetylriboflavin, a chemical derivative from RF) was used as PDT agent.



592
593
594 **Fig. 3.** (A) Cyclic voltammetry (CV) analysis of RTA (blue), RF (red) and 0.1 M PBS
595 (pH 7.0, black) between -0.8 and 0.2 V vs. Ag/AgCl at a scan rate of 100 mV/s; (B)
596 Differential pulse voltammetry (DPV) analysis RTA (blue), RF (red) and 0.1 M PBS
597 (pH 7.0, black) between -0.8 and 0.2 V vs. Ag/AgCl at a scan rate of 100 mV/s.
598






Fig. 4. (A) TEM image of NaYF₄:Yb/Tm nanoparticles; and (B) TEM image of mesoporous silica-coated NaYF₄:Yb/Tm nanoparticles.




604
605
606 **Fig. 5.** (A) Emission fluorescence spectrum of NaYF₄:Yb/Tm nanoparticles excited
607 under 980nm-NIR irradiation; and (B) UV-visible absorbance spectra of the RTA and
608 RF solutions.
609



610

611


612 **Fig. 6.** Photostabilities of RF, RTA, RF/UCNP, and RTA/UCNP under different
613 conditions (visible irradiation or 980nm-NIR irradiation). A 50-W Xe-arc lamp
614 (XD-300, Nanjing Yanan Co., China) equipped with an UV-cutoff (>400 nm) was
615 used as visible light source and a 980 nm NIR laser (MDL-980, Changchun New
616 industries optoelectronics tech. Co., China) was used as NIR light source. Initial
617 concentrations of different solutions: RF solution of $10 \mu\text{M}$; RTA solution of $10 \mu\text{M}$;
618 RF/UCNP solution of 5 mg/mL ; RTA/UCNP solution of 5 mg/mL).



619

620

621 **Fig. 7.** ROS generation in RTA/UCNP solution (5 mg/mL) under NIR irradiation (980
 622 nm): (A) EPR spectra of 4-oxo-TEMP/ $^1\text{O}_2$ generated in aqueous solution (pH 7.0) and
 623 Simulation of EPR spectra of 4-oxo-TEMP/ $^1\text{O}_2$; (B) EPR spectra of the DMPO/ $\text{O}_2^{\bullet-}$
 624 generated in VB₂ solution (dimethyl sulfoxide) and Simulation of EPR spectra of
 625 DMPO/ $\text{O}_2^{\bullet-}$; and (C) EPR spectra of DMPO/ $\bullet\text{OH}$ produced by RTA/UCNP solution
 626 (pH 3.0) in the presence of Fe^{2+} (5 μM) and Simulation of EPR spectra of
 627 DMPO/ $\bullet\text{OH}$.



628

629

630

631

632

633

634

635

Fig. 8. MDA-MB-231 cancer cell viability: (A) PS/UCNP composites (5 mg/mL) after different exposure time to 980nm-NIR irradiation (5, 10, 20, and 30min); (B) Different concentration of PS/UCNP (0.625, 1.25, 2.5, and 5 mg/mL) after 10-minute NIR irradiation; and (C) Effect of Fe²⁺ under 980 nm-NIR irradiation. 48 hours after irradiation, cell death was measured and bar graphs represent means of triplicates±standard deviation.

Graphical Abstract

